larotrectinib
bayer
['larotrectinib']
rapid and durable responses continue to be demonstrated with larotrectinib in pediatric patients with tropomyosin receptor kinase fusion-positive cancer. #pedcsm #asco22 
Oncology news and insights from leading researchers and cancer centers.